ACC (Cardiology)
AI-Enabled Clinician: Navigating Large Language Models in Cardiology
In this episode, Chief Innovation Officer Dr. Ami Bhatt and Dr. Ankeet Bhatt explore the impact of large language models (LLM) on cardiovascular care today.
Latest medical news · page 93
The latest headlines across every section, pulled from official and open-access sources.
Fierce Biotech
City aims to lay foundation for RNAi renaissance with nearly $100M series B
Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics has landed a nearly $100 million series B to fund a clinical push and power further development of its foundational platform.
Fierce Biotech
ADA: Dexcom CGM shows benefit in non-insulin diabetes patients
A Dexcom continuous glucose monitor helped adults with type 2 diabetes not using insulin improve blood sugar control in a randomized trial, adding new fuel to the industry’s push to bring CGMs into broader primary care use.
Fierce Biotech
ResMed snaps up Noctrix Health in $340M sleep tech deal
ResMed has closed its $340 million acquisition of Noctrix Health, picking up a wearable neuromodulation device that pushes the sleep tech giant beyond its core sleep apnea and respiratory care businesses.
Fierce Biotech
Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger
Treeline Biosciences, an under-the-radar cancer company that has raised more than $1 billion since its 2021 founding, is looking to step into the spotlight of the public market. Treeline has announced plans to merge with omics outfit Standard BioTools and secure a listing on the Nasdaq.
Fierce Biotech
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio
Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate platform via the acquisition of Firefly Bio.
Fierce Biotech
Incyte inks $2B deal to add Star unit to late-phase constellation and challenge Takeda
Incyte has struck a deal to buy a Star Therapeutics subsidiary for $1.25 billion upfront. The takeover, the biggest bet of Bill Meury’s time as CEO, covers a late-phase bleeding disorder drug candidate that could support Incyte’s ambition to grow through the loss of patent protection for Jakafi in 2028.
Fierce Biotech
GSK pledges £44.5M in near term for UK biotech to explore cause of liver fibrosis regression
GSK’s latest hepatology partnership is posing a less-asked question—how do you encourage the regression of patients’ liver fibrosis?
Fierce Biotech
How integrated strategy is reshaping biopharma growth
RevHealth CEO Ben Beckley shares how integrated teams are helping biopharma organizations align strategy, break down silos and drive stronger commercial impact.
Fierce Biotech
Managing complexity across biopharma modalities
SK pharmteco CEO Joerg Ahlgrimm discusses complexity, global pressure and drug development speed.
Fierce Biotech
How AI is reshaping biopharma decision-making
AI is accelerating discovery, but only when paired with expert insight and trusted data. Hear how leaders are rethinking decision-making in biopharma.
Fierce Biotech
Could engaging the immune system improve AML outcomes?
With unmet need still high in AML, new approaches are exploring whether engaging immune responses could help improve long-term disease control.
Fierce Biotech
How Unlearn is building a scientific intelligence layer for clinical development
Unlearn founder and head of AI, Aaron Smith, on how digital twins are moving from trial simulation into the full chain of decisions sponsors make — and what regulators need to see along the way.
Fierce Biotech
Why Execution Excellence Now Defines Biopharma Winners
Strategy matters—but execution separates leaders. Hear how top biopharma teams translate strategy into results.
Fierce Biotech
Why AI is changing clinical development
PhaseV CEO Raviv Pryluk explains how AI is reshaping trial design and execution.
Fierce Biotech
Biotech value creation at an inflection point
Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.
Fierce Biotech
Biopharma IPOs: Timing, capital and staying flexible
Regulatory shifts, tight capital and volatile IPO windows are reshaping biopharma strategy. Hear how leaders are adapting.
Fierce Biotech
Biopharma moves to reduce development risk earlier than ever
Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.
Fierce Biotech
Executive Interviews at Fierce Biotech Week 2026
Discover how these trailblazers are accelerating breakthroughs, forging impactful partnerships, and redefining what’s possible in life sciences. Access the exclusive interviews below to get inspired and stay ahead of the curve.
Fierce Biotech
Why City of Hope Built a National Clinical Trials Platform Designed to Scale With Oncology Innovation
City of Hope built a national trials engine to move oncology innovation faster, wider and with the scale sponsors need.
Fierce Biotech
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 trial.
Fierce Biotech
ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update
A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.
Fierce Biotech
ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog, petrelintide.
Fierce Biotech
ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
Even as Zepbound fires on all cylinders and Foundayo gets off to the races in the oral market, Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.